About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- Human, premenopausal women with HSDD, two trials, combined n approximately 1247, multicentre
- Sample size
- approximately 1247 (combined)
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Industry-sponsored (Palatin Technologies); disclose as a conflict-of-interest factor. Otherwise the strongest-designed human evidence identified in this batch.
Cited in
The RECONNECT Phase 3 trials
PT-141 (Bremelanotide) · Research finding
Strong
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.